Protein binding of indobufen enantiomers: Pharmacokinetics of free fraction - Studies after single or multiple doses of rac-indobufen

Chirality

Volumn 14, Issue 9, 2002, Pages 736-741

  Główka, Franciszek K ^a   Caldwell, John ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

( ) R and (+) S indobufen enantiomers; Free and total concentration; Patients; Pharmacokinetics; Protein binding; Racemate; RP HPLC, volunteers; Ultrafiltration method

Indexed keywords

INDOBUFEN; PLASMA PROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BINDING SITE; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENANTIOSELECTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; ULTRAFILTRATION;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; PHENYLBUTYRATES; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; STEREOISOMERISM;

EID: 0036381071     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.10137     Document Type: Article

References (19)

1. Inhibition of platelet function with indobufen: Correlation with plasma drug level
2. Effects of racemic, S- and R-indobufen on cyclooxygenase and lipooxygenase activities in human whole blood
3. The (+)-enantiomer is responsible for the antiplatelet and antiinflammatory activity of (±)indobufen
4. The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man
5. Indobufen. An updated review of its use in the management of atherothrombosis
6. The dispositional enantioselectivity of indobufen in man
7. Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man
8. Stereoselective pharmacokinetics of indobufen from tablets and intramuscular injections in man
9. Steady-state pharmacokinetics of indobufen enantiomers in patients with obliterative atherosclerosis
10. Influence of protein binding and use of unbound (free) drug concentrations
11. LC procedure with SPE for quantification of indobufen enantiomers: Pharmacokinetics studies
12. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs
13. Research methodology in NSAID, monitoring: Plasma concentrations of chiral drugs
14. Influence of indobufen on occlusion of arteriovenous fistulas and some platelet activity in intermittent peritoneal dialysis patients
15. Stereoselective, competitive, and nonlinear plasma protein binding of ibuprofen enantiomers as determined in vivo in healthy subjects
16. Species differences of serum albumins. III. Analysis of structural characteristics and ligand binding properties during N-B transitions
17. Binding of nonsteroidal anti-inflammatory agents and their effect on binding of racemic warfarin and its enantiomers to human serum albumin